GSK plc has announced a definitive agreement to acquire RAPT Therapeutics for $2.2 billion, which includes ozureprubart, an anti-IgE therapy for food allergies, with a closing expected in early 2026. The acquisition aims to enhance GSK's pipeline and address a significant medical need for food allergy treatments.